ClinicalTrials.gg
WithdrawnNCT02219373Updated Oct 8, 2026

Gabapentin and Oxcarbazepine for Chronic Neuropathic Pain in Children and Adolescents: A Clinical Effectiveness Study

A Phase 3 interventional study of Gabapentin and Oxcarbazepine in Pediatric Chronic Neuropathic Pain, sponsored by Boston Children's Hospital. Withdrawn at 1 site in United States. Open to participants aged 8 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Boston Children's Hospital · Phase 3, Interventional, and Treatment

How we know

Why this study was withdrawn
Study was withdrawn for feasibility-related concerns.
Updated Oct 8, 2026Now WithdrawnEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
8 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies testing gabapentin in Neuralgia — 2 open to participants now, 2 under way, none of them phase 3. Gabapentin · Neuralgia.

Enrollment
15th of 17
0 · median 29
Started
2026
with 2 others
Phase 3
4 of 17
none open now
Registered
8th of 17
by date
Lead sponsor
1 of 17
Boston Children's Hospital

Among the 17 studies testing gabapentin in Neuralgia, this one is the 15th largest by enrollment, is one of 3 that started in 2026, is one of 4 in phase 3, and was the 8th registered.

Neuralgia

1,103 studies on the registry are indexed under Neuralgia; 243 are open to participants now.

Browse Neuralgia studies →

Open to participants now

2 of the 17 studies testing gabapentin in Neuralgia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About gabapentin

Gabapentin: first FDA approval 1993 (NEURONTIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 155 Neuralgia studies recruiting now, 79 (51%) set no upper age limit and 44 (28%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 8 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing gabapentin in Neuralgia, or all of them as a file.
02

Study summary

Given the widespread use of anticonvulsants in the pediatric chronic pain population and the absence of scientific data supporting their use, the investigators propose a randomized, double blind, two group parallel design in which a broad group of children and adolescents with chronic neuropathic pain would be randomized to receive either Gabapentin or Oxcarbazepine.

The Primary Aim of the Study is to assess the frequencies of successful treatment of pediatric patients with neuropathic pain treated with either Gabapentin or Oxcarbazepine.

The Primary Hypotheses are as follows:

Hypothesis I: Both Gabapentin and Oxcarbazepine will result in significant reduction in pain scores when compared to each patient's baseline.

Hypothesis II: Patients who continue on active drug (Gabapentin or Oxcarbazepine) during the second phase of the trial will report greater pain reduction relative to baseline than patients who are randomized onto placebo at this randomization point.

Secondary Aims of the Study are to compare groups treated initially with Gabapentin or Oxcarbazepine with regard to reduction in pain scores (both at rest and with evoked maneuvers), functional disability scores, tolerability, and measures of mood and cognitive functioning.

Secondary Hypotheses are that Gabapentin and Oxcarbazepine differ in their effects on:

  1. Pain scores at rest and with evoked maneuvers
  2. Functional disability scores
  3. Tolerability (frequencies of side-effects)
  4. Depression and anxiety scales
  5. Neuropsychological measures of cognitive processing speed, working memory, and attention.
03

Conditions studied

  • Pediatric Chronic Neuropathic Pain

Browse trials for

04

Who can participate

Ages eligible
8 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients between the ages of 8 and 18 at the time of the study with history of chronic (lasting ≥ 4 weeks) neuropathic pain that includes a known injury to a peripheral nerve and/or a pattern of pain responses that includes allodynia, burning, paresthesias or dysesthesias will be included in this study, provided that has been given by parents.
  2. Patient's whose pain rates between moderate to severe at the time of inclusion (ranging from 4-10 in a numeric pain rating scale)
  3. Eligible diagnoses include Complex Regional Pain Syndrome, Fibromyalgia, Lumbar Radiculopathy, Spinal Cord Injury, Erythromelalgia, Small Fiber Neuropathies, Traumatic or Post-surgical Peripheral Nerve or Plexus Injuries, and Extremity Pain with severe pain to light touch (allodynia).
  4. Child has age-appropriate spoken and written knowledge of English.
  5. Parent may be able to utilize an interpreter if need be.

Exclusion criteria

Exclusion Criteria:

  1. Unstable psychiatric illness (suicidal ideation, disorganized behavior)
  2. Uncontrolled Seizure disorder
  3. Chronic Headaches only
  4. Abdominal Pain only
  5. Prior experience with anticonvulsants for pain treatment.
  6. Patients with Syndrome of Inappropriate Secretion of Antidiuretic Hormone
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Gabapentin

    Drug: Gabapentin · Other: Placebo

  • Experimental
    Oxcarbazepine

    Drug: Oxcarbazepine · Other: Placebo

  • Placebo comparator
    Placebo

    Patients taking placebo will have placebo dose escalated using similar frequency, periods of time, and volumes as those for the active drugs.

    Drug: Gabapentin · Drug: Oxcarbazepine · Other: Placebo

Interventions

  • Patients will be randomized to receive either Gabapentin or Oxcarbazepine. The assignment of the medications will be randomized and blinded to both the study investigators and the patient. If patients exhibit \>30% pain reduction on receiving the medication evaluated after 4 weeks, then they may continue to receive either the same medication or placebo. If patients exhibit \<30% pain reduction, the patient will crossover to the other medication option in the protocol.

  • Patients will be randomized to receive either Gabapentin or Oxcarbazepine. The assignment of the medications will be randomized and blinded to both the study investigators and the patient. If patients exhibit \>30% pain reduction on receiving the medication evaluated after 4 weeks, then they may continue to receive either the same medication or placebo. If patients exhibit \<30% pain reduction, the patient will crossover to the other medication option in the protocol.

  • OtherPlacebo

    Patients taking placebo will have placebo dose escalated using similar frequency, periods of time, and volumes as those for the active drugs.

06

What researchers measure

Primary outcomes

  1. As a primary outcome, success will be defined by clinically and statistically significant within subject reductions in pain scores

    1. 2 point reduction in average daily pain scores 2. 30% reduction relative to baseline 3. Global overall impression of strong benefit.

    Time frame: 0 (baseline), 2, 4, 6, 8 weeks (post-assignment of intervention)

Secondary outcomes

  1. Pain Scores at rest and evoked maneuvers

    The investigators will assess pain scores at rest and with evoked maneuvers through exam and quantitative sensory test.

    Time frame: 0 (baseline) and 4 and 8 weeks (post assignment of intervention)

  2. Frequency of side effects- Tolerability

    * Common side effects include headaches and feeling sleepier in the morning and having less energy. Side effects that can occur, but are not common, include gastrointestinal side effects (upset stomach or throwing up, diarrhea or constipation, and weight gain), feeling lightheaded, having blurred eyesight, shakiness or changes in balance. * Very rarely, patients taking these medicines may experience memory problems, sadness, nervousness, and Serious Adverse Events (SAEs). Routine laboratory testing will be conducted as part of the safety profile assessment.

    Time frame: 1, 2, 4, 6, 8 weeks (post assignment of intervention)

  3. Functional Disability Scores

    Time frame: 0 (baseline), 4, and 8 weeks (post-assignment of intervention)

  4. Frequency of Side effects- Depression and Anxiety

    As both study medicines may be associated with mood changes and as pain itself sometimes is co-morbid with anxiety and depression, the investigators will perform self-report measures of anxiety and depression (Children's Depressive Inventory and The Revised Children's Manifest Anxiety Scale) pre and post-assigment of the intervention.

    Time frame: Baseline, Week 4 and 8 (post assignment of the intervention)

  5. Frequency of Side Effects- Neuropsychological Measures

    Both study medicines may be associated with the emergence of cognitive side effects to include difficulties with concentration and cognitive slowing. The investigators will assess for cognitive processing speed, working memory and attention difficulties during the course of treatment using the NIH toobox Cognitive Battery.

    Time frame: Baseline, weeks 4 and 8 (post-assignment of the intervention).

07

Study locations

1 site
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Dec 2028, 30 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2014
First posted
Aug 18, 2014
StartEst.
Jun 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Withdrawn Study was withdrawn for feasibility-related concerns.
changed Oct 8, 2026
Enrollment
60 (estimated)→0 (actual)
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Not yet recruiting→Withdrawn
    Why stopped Study was withdrawn for feasibility-related concerns.
    Enrollment 60 (estimated)→0 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT02219373
Responsible party
Monique Ribeiro (Physician, Boston Children's Hospital) — Principal investigator
First posted
Aug 18, 2014
Start date
Jun 2026 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 8, 2026

Study contacts

Monique Ribeiro, MD
principal investigator · Boston Children's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gabapentin · Oxcarbazepine

Start the discussion